Decrescendo, NCT04675827: De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade |
|
|
| Terminated | 2 | 139 | Europe, RoW | Pertuzumab and tratuzumab fixed dose combination, Adjuvant pertuzumab + trastuzumab FDC SC for 14 cycles, Fixed-dose combination of Perjeta and Herceptin for subcutaneous injection for 14 cycles, Trastuzumab emtansine, Adjuvant T-DM1 | Jules Bordet Institute, Breast International Group, Hoffmann-La Roche, International Drug Development Institute, Institut Curie | HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer | 11/24 | 11/24 | | |
NCT05388734: Shared Decision Making on Care Pathways and CAMs: A Pilot Study |
|
|
| Recruiting | N/A | 100 | Europe | alternative medicine education consultation | University Hospital, Grenoble, University Grenoble Alps, Laboratoire TIMC-IMAG | Breast Cancer, Non-metastatic, Newly Diagnosed, Feasibility Study | 01/24 | 08/24 | | |
| Recruiting | N/A | 1500 | Europe | Conventional treatment protocols of breast cancer | University Hospital, Grenoble | Breast Cancer | 12/33 | 12/33 | | |
